Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]
Authors:
- Charlie StrangeCSCharlie Strange
- Joseph TkaczJTJoseph Tkacz
- Jill SchinkelJSJill Schinkel
- Benjamin LewingBLBenjamin Lewing
- Barnabie AgatepBABarnabie Agatep
- Sean SwisherSSSean Swisher
- Sushma PatelSPSushma Patel
- Devechio EdwardsDEDevechio Edwards
- Daniel R TouchetteDTDaniel R Touchette
- Edward PortilloEPEdward Portillo
- Norbert FeiglerNFNorbert Feigler
- Michael PollackMPMichael Pollack
Open Access
- 1 August 2024
- journal article
- correction
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 19, 1799-1800
Abstract
Corrigendum for the article Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) StudyKeywords
This publication has 1 reference indexed in Scilit:
- Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) StudyInternational Journal of Chronic Obstructive Pulmonary Disease, 2023